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A genome-wide scan and HCRTR2
candidate gene analysis in a European
cluster headache cohort
L. Baumber, BSc; C. Sjöstrand, MD; M. Leone, MD; H. Harty, BSc; G. Bussone, MD; J. Hillert, MD, PhD;
R.C. Trembath, BSc, FRCP; and M.B. Russell, MD, PhD, DMSci
Abstract—Objective: To investigate the molecular genetic basis of cluster headache (CH), using a genome-wide scan and
candidate gene strategy. Methods: Northern European CH families and a case-control cohort of Danish, Swedish, and
British origin (total n  259 sporadic CH patients), including 267 control subjects matched for ancestry, participated in
the study. A genome-wide genetic screen using approximately 400 microsatellite markers was performed for five informa-
tive Danish CH families. Additional markers were typed for those loci generating statistical evidence suggestive of
linkage, together with genotypes for 111 individuals from further Danish and Italian kindreds. Sporadic CH patients and
controls were investigated by association analysis for variation in the candidate gene, HCRTR2. Finally, complete
HCRTR2 sequencing was undertaken for eight independent probands. Results: Potential linkage was identified at four
possible disease loci in Danish kindreds, yet no single chromosome location generated a lod or NPL score of recognized
significance. No deleterious sequence variants of the HCRTR2 gene were detected by comparison to wild-type sequence.
Association of the HCRTR2 gene was not replicated in this large dataset, even when the data were stratified into distinct
populations. Conclusions: Cluster headache is a complex genetic disorder, with possible phenotypic and genetic heteroge-
neity compounding attempts at gene identification.
NEUROLOGY 2006;66:1888–1893
Cluster headache (CH) is characterized by unilat-
eral, periodic attacks of excruciating pain, accompa-
nied by autonomic dysfunction.1,2 In 10% of
patients, chronic CH features persist.3 The disease
has an estimated prevalence of 1/500,4-6 and displays
marked sex bias (female:male ratio 1:2.5 to 3.5).1,7,8
CH is considered to be a neurovascular disorder with
activation of hypothalamic, trigeminovascular, and
cranial parasympathetic systems.9,10 Altered neuro-
hormone levels11-14 indicate central activation, and
PET studies reveal ipsilateral inferior hypothalamic
gray matter changes during attacks.10,15 Pain relief
by deep brain stimulation of the posterior hypothala-
mus further implicates central activation processes
in disease pathogenesis.16,17
Several observations support a genetic predisposi-
tion to CH. Relative risk for disease is increased,8
while pedigree analysis indicates autosomal domi-
nant segregation, with reduced penetrance.18 Incom-
plete concordance for monozygotic twins with CH8,19
suggests a complex etiology with environmental
involvement.
The molecular basis of CH remains poorly charac-
terized. Mitochondrial mutations seen in two sub-
jects20,21 may be chance findings.22,23 Case-control
analyses of the calcium channel gene CACNA1A and
the nitric oxide synthase genes NOS1, NOS2A, and
NOS3, while good biologic candidates, revealed no
allelic association.24-28 Furthermore, linkage to the
CACNA1A locus has been excluded in a CH family.29
The neuropeptides hypocretin-1 and -2, expressed
within the posterolateral hypothalamus,30 activate
the hypocretin receptor 2 (HCRTR2) and regulate
the sleep-wake cycle, with hypocretin system defi-
ciencies associated with narcolepsy.31 A recent study
in Italian sporadic patients identified a single
HCRTR2 polymorphism associated with CH.32 Here,
we present results from a genome-wide scan in CH
families and seek replication of association to the
HCRTR2 gene.
Methods. Familial Danish, Italian, and Swedish CH patients
were ascertained as described previously.18,33,34 Danish probands,
recruited from two neurologic clinics by a single investigator
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(M.B.R.) and through the Danish patient organization for CH,
were asked to complete a mailed questionnaire detailing any
known family history. Patients of Italian origin, ascertained
through the Headache Centre of the Carlo Besta National Neuro-
logic Institute, all underwent physical and neurologic examination
including cerebral CT or MRI to exclude secondary headache.
Swedish CH patients were collected at the Department of Neurol-
ogy, Huddinge University Hospital, or via the CH network on the
Swedish migraine patients’ Web site (Svenska Migränförbundet;
http://www.migran.org/), and all affected subjects were clinically
examined by a neurologist specialized in headache (C.S.). At all
three centers, probands and their relatives were interviewed ei-
ther directly or by telephone to establish a family history of CH.
The UK subjects were recruited via the Organisation for the Un-
derstanding of Cluster Headaches in the UK (OUCH [UK]; http://
www.clusterheadaches.org.uk/). Criteria used for diagnosis of CH
were consistent between each of the four countries and were as
specified by the International Classification of Headache Disor-
ders.2 Peripheral blood samples were taken from all consenting
familial CH patients (n  167; 69 Danish, 43 Italian, 50 Swedish,
and 5 UK) and their healthy relatives.
CH singletons used in the HCRTR2 association analysis were
ascertained in the same way as familial cases, but reported no
family history of the condition. Control subjects, matched for an-
cestry, were drawn from the general population (Denmark) or
consisted of blood donors, healthy volunteers, or spouses of pro-
bands (Sweden and UK). Table 1 summarizes the clinical charac-
teristics of the case-control cohort.
All patient and control populations were of Caucasian origin.
The study was approved by the relevant local ethics committees
and all participants gave informed consent prior to the study.
DNA extraction and genotyping. Genomic DNA was extracted
from 10 mL of peripheral venous blood using standard techniques.
A genome-wide screen was performed for individuals from five
multigenerational Danish families, using fluorescently labeled mi-
crosatellite markers with an average spacing of 9 cM (Marshfield
Center for Medical Genetics, screening set v10). PCR amplifica-
tions were performed on MJ Research DNA Engines (10 L reac-
tions; 50 ng DNA, 1.5 mM MgCl2, 0.2 mM dNTPs [Pharmacia], 0.2
M each primer, 0.5 U Taq polymerase [ABgene] in a 10  KCl
PCR buffer [ABgene]). PCR products were pooled and electropho-
resed through 6% polyacrylamide gels (Flowgen) on an ABI 377
DNA sequencer. Genotype data were generated using GeneScan
v3.0 and Genotyper v2.1 software (Applied Biosystems). Data for
21 markers that failed to optimize were excluded from further
analysis. Typing was successful for 95% of genotypes at the re-
maining 383 markers (full details available on request to author).
Data for the X and Y chromosomes were used to confirm pedigree
structures but were not included in linkage analyses, as the fre-
quency of affected females and presence of male-to-male transmis-
sion were considered inconsistent with a sex-linked model of
inheritance.
Following statistical analysis of the genome screen data, fur-
ther markers (D2S2299, D2S142, D2S2380, D2S111, D2S130,
D2S2390, D2S401, D2S2213, D8S1755, D8S552, D8S1827,
D8S1731, D9S288, D9S1810, D9S281, and D9S286), selected from
genetic maps at the Marshfield Center for Medical Genetics
(http://research.marshfieldclinic.org/genetics/Map_Markers/maps/
IndexMapFrames.html), were typed for those loci showing evi-
dence of potential linkage. At this stage of analysis, the cohort
was supplemented by inclusion of newly available material,
namely a further 8 family members (3 affected) from families D42,
D162, and D651, plus 111 additional individuals (60 affected) from
16 Danish and 12 Italian kindreds. Table 2 summarizes the char-
acteristics of all CH kindreds used in linkage analyses.
For the SNP genotyping, DNA samples were arranged into
96-well microtiter plates, comprising 259 unrelated sporadic CH
patients and 267 ethnically matched control subjects. Patients of
Italian origin were omitted from the HCRTR2 association analysis
due to the small sample size and lack of a suitable control popula-
tion (see table 1). Two polymorphisms of the HCRTR2 gene
(rs3122169 and rs2653349 from NCBI dbSNP; http://www.ncbi.
nlm.nih.gov/SNP/) were amplified from plated DNA samples using
sequence-analysis primers for exons 2 and 5, and resultant prod-
ucts were dot-blotted onto Hybond N (Amersham). SNPs were
typed by ASO hybridization using a tetramethylammonium chlo-
ride (TMAC) hybridization protocol.35 Alleles were assigned by
direct examination of autoradiographs compared for each allele.
HCRTR2 sequencing. The complete protein-coding region and
intron/exon boundaries, including splice donor/acceptor sites, 3=
UTR, and 200 bp of flanking 5= UTR, of the HCRTR2 gene were
amplified by PCR in 40 L reactions for an affected subject from
each of eight independent families, namely D42, D162, ITA6,
ITA48, SWE13, SWE14, UK1, and UK5, plus one normal control
individual. PCR products were separated by electrophoresis
through 2% LE agarose (FMC Bioproducts) to ensure the presence
of sufficient quantities for sequence analysis, and were then puri-
fied using the QIAquick PCR purification kit (Qiagen). Purified
PCR products were sequenced with the Applied Biosystems Big-
Dye terminator kit, and were electrophoresed through 5% Long-
Ranger (Cambrex) polyacrylamide gels on an ABI 377 automated
sequencer (Applied Biosystems). Sequence traces were analyzed
with Sequence Analysis v3.2 and SeqEd v1.0.3 computer software
(Applied Biosystems).
Statistical analyses. Family-based data were first analyzed
using the simulation program SLINK,36,37 to establish the cumula-
tive power to detect significant evidence for linkage contained in
the five largest Danish families (D42, D150, D162, D651, and
D799). These families were selected as they consisted of three or
more affected individuals, distributed across at least one genera-
tion. Marker data were generated randomly for 1,000 replications,
and simulated datasets analyzed under a disease model of autoso-
mal dominant inheritance with a reduced penetrance of 30%. A
Table 1 Clinical characteristics of the cluster headache (CH)
case-control cohort
Cases Danish Italian Swedish UK
Sporadic cases, n 96 11 100 63
No. of chronic CH 6 4 4 N/K
No. of episodic CH 90 7 96 N/K
Male 65 9 76 43
Female 31 2 24 20
Mean age at onset,
y (range)
31.8 (5–65) 23.9 (18–36) 29.7 (11–63) N/K
Control subjects, n 72 0 106 89
Male 50 — 68 47
Female 22 — 38 42
Distinction between chronic and episodic CH and details of age at onset
were not recorded for the UK cohort.
N/K  not known.
Table 2 Clinical characteristics of cluster headache (CH)





No. of families 21 12 33
Total no. of individuals
genotyped
125 37 162
Mean no. of subjects per
family (range)
6.0 (2–15) 3.1 (2–7) 4.9 (2–15)
Total no. of affected subjects
genotyped
56 26 82
Mean no. of affecteds per
family (range)
2.7 (2–6) 2.2 (2–4) 2.5 (2–6)
Total no. of chronic CH cases 6 0 6
Male 3 — 3
Female 3 — 3
Mean age at onset, y (range) 35 (18–56) — 35 (18–56)
Total no. of episodic CH cases 50 26 76
Male 37 17 54
Female 13 9 22
Mean age at onset, y (range) 26.1 (7–52) 23.5 (10–50) 25.2 (7–52)
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disease allele frequency of 0.001 and a phenocopy rate of 0.001
were assigned. Simulations were performed in duplicate, assum-
ing locus homogeneity and heterogeneity, with percentages of
linked families designated at 100% and 70%.
The computer program GAS (Genetic Analysis System v2.0;
Alan Young, Oxford 1993–1995) was used to format genotype data
for linkage analysis, to verify inheritance, and to calculate marker
allele frequencies. Any identified inconsistencies were corrected by
re-assessment of original GeneScan files and, if necessary, re-
genotyping. If anomalies could not be resolved after a second
round of genotyping, data for all family members were removed to
avoid potential biasing.
Single- and multipoint linkage analyses were performed using
Genehunter v2.1.38 lod Scores were calculated using the disease
model described above. Due to potential ambiguity for the mode of
transmission in CH, Genehunter was also used to generate model-
free nonparametric NPL scores for each analysis. For those loci
reaching a lod or NPL score of 2.0 or above, corresponding to the
criteria of potentially interesting,39 four additional markers span-
ning each locus with an average spacing of 2 cM were next
analyzed.
Association analysis of HCRTR2 SNP data were assessed us-
ing a 2 test, to compare both allele and genotype frequencies
between case and control populations. Hardy-Weinberg equilib-
rium was observed in CH cases and controls and significance was
established at p  0.01.
Results. Linkage analysis. We chose five extended kin-
dreds to perform simulations of linkage using the SLINK
program. Estimates of the maximum lod score, based on
all markers and subjects being informative, achieved val-
ues of 3.35 and 3.17, under models of disease locus homo-
and heterogeneity. Furthermore, the likelihood of reaching
a combined lod score of 3 by chance alone was calculated
as 1.6% of the replicates, which decreased to 0.2% if a
model of more than one disease locus for CH was applied.
Using real genotype data, we performed single- and
multipoint linkage analyses to generate lod and NPL
scores for each autosome. The results from the complete
genome screen gave no significant support for linkage to a
single chromosomal region. However, lod and NPL scores
either potentially interesting or suggestive of linkage
(2.0) were obtained for two distinct loci on chromosome 2
(markers D2S1353; 164.51 cM, and D2S1363; 227.0 cM),
and one locus on each of chromosome 8 (GATA151F02;
27.4 cM) and chromosome 9 (D9S2169; 14.23 cM). The
figure illustrates the two-point lod and NPL scores com-
bined with the multipoint linkage analyses.
For each of the loci demonstrating potential linkage,
four additional markers were typed and genotype data an-
alyzed for the whole chromosome to extract maximum in-
formation from the Genehunter analysis package. Of the
four loci examined, inclusion of additional markers main-
tained support of potential linkage at the GATA151F02
locus on chromosome 8 alone. Multipoint linkage analysis
generated NPL scores over 2.0 for three of the four flank-
ing markers (NPLmax  2.32 for distal marker D8S1827).
Single point analysis failed to support linkage to newly
typed markers flanking any of the initial loci investigated.
Genotype data for each of the four distinct potentially
linked loci were next analyzed in 60 further subjects, as-
certained primarily as nuclear kindreds with two or more
affected individuals. Pedigrees were subdivided into Dan-
ish and Italian cohorts, to establish whether individual
populations provided evidence of linkage to distinct loci,
before repeating the analyses for the combined dataset.
The Danish cohort (consisting of families D42 to D799 plus
16 new pedigrees) provided no evidence of linkage to any of
the identified loci, generating a maximum combined multi-
point NPL score of 1.82 at D8S1827, and a maximum sin-
gle point NPL of 1.41 for GATA151F02. In contrast,
analysis of a small Italian cohort generated compelling
support for linkage to chromosome 9, with multipoint NPL
scores of 2.19 and 2.41 (p  0.0098) for markers D9S2169
and D9S281 observed. These scores were not maintained
when Danish and Italian populations were combined.
Mutation analysis and association study of
HCRTR2. To determine whether a pathogenic mutation
of the HCRTR2 gene might explain the familial occurrence
of CH in our kindreds, we performed sequencing of
Figure. Graphs illustrating results of chromosome specific
linkage analyses from genome-wide scan. Data identifying
regions of potential linkage (designated as NPL/lod  2.0)
are displayed, with distance along the chromosome in cen-
tiMorgans (x-axis) and lod/NPL score (y-axis). Solid lines
represent multipoint NPL scores; dashed lines, multipoint
lod scores. Filled squares illustrate two-point NPL scores;
filled triangles, two-point lod scores.
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genomic DNA for a single affected subject (total n  8)
from each of two independent families of Danish, Italian,
Swedish, and British origin. No deleterious sequence vari-
ants were detected by comparison to wild-type control
sequence.
Table 3 shows the genotype and allele frequencies ob-
served for each of the HCRTR2 single nucleotide polymor-
phisms examined. For the intronic SNP [rs3122169] we
detected no significant difference in allele or genotype fre-
quencies between the patient and control populations, us-
ing a 2 test of probability. Results for the 922G/A
polymorphism in exon 5 [rs2653349], previously reported
to be associated with CH, showed no difference in either
genotype or allele frequencies in our diverse CH cohort,
when compared with a matched control population. To es-
tablish whether the tested polymorphisms showed an asso-
ciation with CH in individual cohorts, the same data were
stratified into distinct populations. Again, we detected no
significant difference for either genotype or allele frequen-
cies between CH patients and ethnically matched controls
(table 4). Further stratification by sex, taking into account
the sex bias observed in CH, also provided no support for
association (data not shown).
Discussion. Anticipating the complexity of inher-
ited predisposition to CH, we initiated a European
collaboration to pool material from probands, sib-
ships, and multiplex extended kindred ascertained
across Northern Europe. To date, this cohort com-
prises subjects ascertained from 84 independent kin-
dreds with CH (167 affected subjects) and 270
sporadic CH cases. In this study, we sought to iden-
tify gene locations implicated in disease predisposi-
tion by performing a medium (9 cM) density genome-
wide scan. In addition, we sought replication of a
specific candidate gene identified through an associ-
ation study.
We assessed five multiplex kindreds, each of Dan-
ish origin, using a parametric model of a CH gene
acting as an autosomal dominant trait with 30% pen-
etrance. No significant lod scores were identified for
any locus across the genome. We next performed a
model-free (nonparametric) based analysis, and iden-
tified potentially interesting scores for four loci,
namely chromosome 2, D2S1353; chromosome 2,
D2S1363; chromosome 8, GATA151F02; and chromo-
some 9, D9S2169. To further interrogate these re-
gions of putative interest, we next studied an
extended collection of Danish and Italian kindreds,
together with additional independent subjects. We
typed further STS markers for each region and, de-
spite adequate power to detect linkage under as-
sumptions of homogeneity, no single locus reached
significance. In conclusion, we were unable to specify





2 p ValueAA AC CC A C
c.224-26AC [rs3122169]
CH patients 258 172 (66.7) 80 (31.0) 6 (2.3) 2.86* 0.239 424 (82) 92 (18) 0.273† 0.603
Controls 238 159 (66.8) 67 (28.2) 12 (5.0) 385 (81) 91 (19)
c.922GA [rs2653349] GG GA AA G A
CH patients 257 165 (64.2) 84 (32.7) 8 (3.1) 2.73* 0.255 414 (81) 100 (19) 1.80† 0.180
Controls 267 161 (60.3) 90 (33.7) 16 (6.0) 412 (77) 122 (23)
* Two degrees of freedom.
† One degree of freedom.
GF  genotype frequencies; AF  allele frequencies.
Table 4 Stratification of SNP data into ascertainment populations
c.224-26AC [rs3122169] c.922GA [rs2653349]
GF (%) AF (%) GF (%) AF (%)
n AA AC CC A C n GG GA AA G A
Danish cohort
CH patients 96 61 (63.5) 33 (34.4) 2 (2.1) 155 (81) 37 (19) 96 56 (58.3) 38 (39.6) 2 (2.1) 150 (78) 42 (22)
Controls 69 40 (58.0) 26 (37.7) 3 (4.3) 106 (77) 32 (23) 72 37 (51.4) 31 (43.1) 4 (5.6) 105 (73) 39 (27)
Swedish cohort
CH patients 99 72 (72.7) 24 (24.2) 3 (3.0) 168 (85) 30 (15) 98 68 (69.4) 26 (26.5) 4 (4.1) 162 (83) 34 (17)
Controls 84 60 (71.4) 19 (22.6) 5 (6.0) 139 (83) 29 (17) 106 67 (63.2) 32 (30.2) 7 (6.6) 166 (78) 46 (22)
UK cohort
CH patients 63 39 (61.9) 23 (36.5) 1 (1.6) 101 (80) 25 (20) 63 41 (65.1) 20 (31.7) 2 (3.2) 102 (81) 24 (19)
Controls 85 59 (69.4) 22 (25.9) 4 (4.7) 140 (82) 30 (18) 89 57 (64.0) 27 (30.3) 5 (5.6) 141 (79) 37 (21)
GF  genotype frequencies; AF  allele frequencies.
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a solitary disease locus for the CH phenotype using
the available dataset.
CH rarely occurs in families as a monogenic trait
and our data might suggest locus heterogeneity un-
derlying inherited predisposition to familial CH.
This observation would parallel similar findings in
other forms of genetically determined headache. For
example, molecular genetic studies have identified
mutations in at least two causative genes, CACNA1A
and ATP1A2, in familial hemiplegic migraine, a rare
autosomal dominant form of migraine associated
with aura.24,40 However, recent genome-wide screens
in common migraine suggest other, as yet uncharac-
terized, genes may contribute to this group of disor-
ders, with identification of susceptibility loci on
chromosomes 4q, 6p12.2-p21.1, 11q24, 14q21.2-
q22.3, 15q11-q13, and Xq24-q28,41,42 together with
evidence of suggestive linkage to chromosomes 3q
and 18p11.43
The discovery that inherited forms of headache
can develop through disruption of specific ion chan-
nels provides important insight as to mechanistic
defects of potential relevance to CH and thereby sug-
gest numerous candidate genes and loci for examina-
tion. However, a number of clinical features and
characteristics typical of CH suggest the likely in-
volvement of alternative pathways underlying dis-
ease predisposition. For example, the periodicity of
attacks implies a potential defect within the supra-
chiasmatic nucleus of the hypothalamus, a key neu-
rogenic regulator of the human biologic clock and
which has been shown to become activated during a
cluster attack.10 Furthermore, the severity of pain
associated with CH compared to other types of head-
ache might suggest a unique pathophysiology for this
disorder. A recent report of association between a
polymorphism in the hypocretin receptor gene,
HCRTR2, in a cohort of sporadic CH patients ascer-
tained within Italy, might provide additional evi-
dence for the role of genetic factors in disease
predisposition.32 However, there is now compelling
evidence that initial candidate gene association stud-
ies carry a high likelihood of false-positive results,
an observation that stresses the need for balanced
publication of replication studies that might (rarely)
confirm or (commonly) reject novel association re-
sults.44 Here we examined two polymorphisms which
include the associated coding sequence variant
(c.922GA) in a larger sample size, with greater
than 95% power to detect association under identical
conditions of replication. We detected no significant
support for allelic association at the HCRTR2 locus.
Stratification of association data into discrete popu-
lations failed to yield evidence for association of ei-
ther SNP with CH. Furthermore, we found no
evidence of linkage to chromosome 6p12.1 within our
family based genome-wide scan. Finally, we per-
formed sequence analysis of genomic DNA for the
entire coding region of HCRTR2 in eight probands
from CH families and detected no pathogenic se-
quence variants. Hence, and in contrast to the origi-
nal report, we find no evidence for even marginal
effects of variants within the HCRTR2 gene in the
European cohorts investigated here. However, our
study cannot exclude the possibility that other vari-
ants may be either disease causing or in linkage
disequilibrium with disease causing variants that
are specific to one or more populations. In this re-
gard, it should be noted that the association analysis
did not include any subjects ascertained in Italy as
we do not have an adequate population-based control
cohort for that region. The potential for hidden pop-
ulation stratification as an explanation for the con-
flicting results from the studies looking at
association between HCRTR2 and CH is further un-
derlined when we note the marked variation in allele
frequencies of this gene in different control cohorts
(see table 4).32 At this stage of investigation into the
genetic basis of CH, our findings argue strongly for
careful attention to methodologic detail. For exam-
ple, further linkage studies will require large sample
sizes or extended pedigrees with multiple affected
subjects, ideally ascertained prospectively to deal
with inherent concerns of historical records of the
CH phenotype in previous generations. For associa-
tion studies, this work adds further to the call for
collaboration between centers working in this field
as sample size and independent replication within a
study should be the gold standard of future reports.45
This report suggests that genetic predisposition to
CH is liable to be complex and likely compounded by
locus heterogeneity and variation in genes conferring
only a small effect size. Despite recent progress in
therapeutic strategies for the management of CH, a
detailed understanding of the etiology and pathogen-
esis remains the most plausible means of compre-
hensive and targeted approaches to the treatment of
this debilitating disorder.
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